Washington Fast-Tracked Psilocybin This Year — Your Local VA Still Can't Prescribe It

Four psilocybin stories broke in the same six-week window this summer, and if you only read headlines you’d think the mushroom is basically legal now. It isn’t.

In April, the FDA handed out three National Priority Vouchers — a new fast-lane that shrinks the usual 10-to-12-month drug review down to one or two months once a company files. Compass Pathways got one for its synthetic psilocybin, COMP360, aimed at treatment-resistant depression (depression that hasn’t responded to at least two prior medications). Usona Institute got one for psilocybin in major depressive disorder. Transcend Therapeutics got one for methylone, an MDMA-like compound, for PTSD. In August, a Nature Medicine trial out of the NHS reported that a single 25-milligram dose of psilocybin cut depression scores by a huge margin in treatment-resistant patients. In July, a Nature Communications brain-imaging study out of UCSF and Imperial College London showed a single high dose leaving measurable traces in the brain a month later. And in early August, the Department of Veterans Affairs opened a five-site trial testing psilocybin in veterans with depression and PTSD that hasn’t budged with standard care.

Here’s my take: this is the most real momentum psilocybin has had since Nixon signed the Controlled Substances Act, and it still won’t put a legal dose in anyone’s hands before 2027 at the earliest.

Start with the drug itself, because the coverage assumes you already know what it is. Psilocybin is the compound in “magic mushrooms” that your body converts to psilocin, which acts on serotonin receptors in the brain — the same broad neurochemical system targeted by antidepressants like SSRIs, but through a completely different mechanism, producing a several-hours-long altered state rather than a daily mood adjustment.

The FDA voucher isn’t approval. It’s a queue-jump. Compass still has to finish and file a rolling New Drug Application — company filings say the final submission is targeted for the fourth quarter of 2026, meaning a decision realistically lands late 2026 or early 2027, and only if the data holds up. Even then, psilocybin stays a Schedule I controlled substance — the DEA’s most restrictive tier, legally defined as having no accepted medical use — until a separate rescheduling process runs its course, and as of this writing no rulemaking notice has been published. FDA approval and DEA scheduling are two different federal machines that don’t move in lockstep. That’s the gate nobody puts in the headline: a company can win approval and the drug can still be a felony to possess outside a licensed clinical setting until DEA acts, which historically takes months to years, not weeks.

The VA trial makes that gap concrete. The agency is running a genuine, five-site randomized study — Birmingham, Tuscaloosa, Portland, Philadelphia, Seattle — comparing psilocybin doses in veterans with depression that hasn’t responded to treatment, some with co-occurring PTSD. VA Secretary Doug Collins said “far too many Veterans are living with mental health conditions that don’t respond to available treatments.” True. But the VA’s own announcement is explicit: clinical use outside research “will only be considered by VA once FDA approval is granted.” If you’re a veteran reading this hoping your provider can write you a psilocybin referral next year, the honest answer is: only if you can get into one of those five trial sites, and only as a research subject, not a patient.

Now the part that should actually change how you think about the drug, not just when you can get it. The NHS trial, run by J.J. Rucker’s team and published in Nature Medicine, randomized 60 adults with treatment-resistant depression to a single 25-mg dose of psilocybin or placebo, both paired with psychological support. At six weeks, the psilocybin group’s depression scores (measured on the MADRS scale, a standard 10-item clinician-rated depression severity tool) had dropped by nearly 13 points more than placebo — a Cohen’s d of 2.11, which in plain terms is a very large effect for a psychiatric trial, where anything above 0.8 is usually called large. Half the psilocybin group hit a meaningful response by six weeks versus 3% on placebo. That’s real. It’s also 60 people at one site, and the researchers themselves flagged the obvious problem: you can’t actually blind someone to whether they just took a psychedelic. If you felt nothing happen, you know you got placebo, and that expectation alone can shape how you rate your own mood afterward. Big effect, small trial, unresolved blinding problem — all three things are true at once, and any coverage that only tells you one of them is selling something.

Big effect, small trial, unresolved blinding problem — all three things are true at once, and any coverage that only tells you one of them is selling something.

The brain study adds a mechanism to that psychology. Researchers gave 28 healthy volunteers with no psychedelic history a placebo-level dose, then a full 25-mg dose a month later, tracking them with EEG, functional MRI, and diffusion tensor imaging — a scan that maps the brain’s white-matter wiring. They measured a spike in what researchers call brain entropy, meaning the brain’s electrical activity became more variable and less locked into its usual repetitive patterns, peaking within an hour of dosing. A month out, imaging showed denser neural tract integrity — the opposite of what typically happens with age-related decline — and the people who reported the deepest psychological insight during the trip had the best mood outcomes weeks later. That’s a real, measurable link between what the drug does to a brain circuit and what it does to how someone feels afterward. It’s also 28 healthy people with no depression, no trauma, no addiction history, in a controlled lab — not you, if you’re reading this in early recovery wondering whether a mushroom trip six years ago actually changed anything permanent, or whether the insight you felt on it was as real as it seemed at 3 a.m.

None of this is new territory reopening for the first time. Psilocybin and LSD research was essentially frozen for three decades after the 1970 Controlled Substances Act placed both in Schedule I, killing federal funding and burying a body of 1950s–60s clinical work almost entirely. The field didn’t restart through Congress — it restarted through one lab. In 2000, Roland Griffiths at Johns Hopkins got government sign-off to dose healthy volunteers again, and his 2006 paper on psilocybin-occasioned “mystical-type experiences” became the study every psychedelic researcher since has had to cite. It took another two decades to get from that single quiet lab to a federal voucher program. The 2026 momentum isn’t a sudden discovery — it’s the compounding interest on research that one team kept alive when almost nobody else was allowed to touch it.

So where does that leave you, in the middle of federal psychedelics policy, if you’re weighing this for yourself, or for a client, or for a family member circling the idea of a legal psilocybin therapy? Not “wait and see” — actually wait. The trial data is genuinely promising and the mechanism research is genuinely interesting, but neither one is a treatment you or your provider can access outside a research protocol right now, and the Schedule I status that makes unsupervised use a federal crime hasn’t moved an inch. The FDA’s public hearing on psychedelic drugs is set for September 14, 2026 — that’s the next real marker to watch, not the vouchers, not the headlines, and not anyone selling you a shortcut before the agencies actually move.